Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

argenx SE

35 indications, side-by-side phase, drug & LoA

$862.18

-21.82 (-2.47%)

C 58Pipeline Score Richly Valued Biotech · Commercial
Market Cap
50.32 B
EPS
21.10
P/E Ratio
41.18 $
Value Trade
253.48 M
-1.63 %
Week
0.18 %
1 Month
-5.07 %
3 Month
-12.2 %
6 Month
197.06 %
5 Year
4,405.36 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
349.30 K
52 Week Range
510.06 - 934.62
% held by Insiders
0.29 %
% held by Institutions
46.32 %
Enterprise Value
45.93 B
Total Shares
61.88 M
Short %
2.93 %
Float Shares
61.71 M
Company Description
Employees:1,863
https://www.argenx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 Readout example
ARGX-121 Not specified
Phase 1
—
Biologics
Rare Diseases
ARGX-121 Not specified
Phase 1
—
Biologics
Rare Diseases
ARGX-121 Not specified
Phase 1
—
Biologics
Rare Diseases
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C58
Pipeline Score
$6.1B
Pipeline Value
Richly Valued
Valuation Signal
18
Drugs Scored
0.1x
rNPV / MCap
Top 85%
Large Pharma
(rank 137 of 905)
Percentile Rank
argenx SE carries a moderate pipeline score (58/100), with $6.1B risk-adjusted pipeline value, led by Empasiprubart in Multifocal Motor Neuropathy (MMN) (Phase 3), across $95B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
empasiprubart
Monoclonal antibody		Chronic Inflammatory Demyelinating PolyneuropathyPhase 3NCT0692000451% $1.2B RECRUITING 378 AVERAGE B (69) Sep 1, 2030MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
ARGX Clinical Trial Results & History
Drug Name Indications Phase Date Trial Results Summary Title Source
VYVGART® (efgartigimod alfa)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2
2025-06-23
VYVGART® (efgartigimod alfa)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2
2025-06-23
VYVGART® (efgartigimod alfa)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2
2025-06-23
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ARGX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
argenx SE (ARGX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ARGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ARGX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ARGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest argenx SE (ARGX) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ARGX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Myasthenia Gravis #1 of 19 PHASE 3 Efgartigimod
AZN NVS JNJ
$2.18B 0.87 LEADER
Autoimmune Disorders #1 of 10 PHASE 3 Efgartigimod PH20
ROIV AZN PFE
$25.4B 0.71 LEADER
Neuropathy #2 of 20 PHASE 3 Empasiprubart + IVIG
VRTX SNY TAK
$8.0B 0.91 LEADER
Thrombocytopenia #3 of 18 PHASE 3 efgartigimod PH20
NVS TAK AMGN
$1.85B 0.85 CONTENDER
Myelodysplastic Syndromes #4 of 33 PHASE 3 Empasiprubart + IVIG
BMY ABBV TAK
$2.5B 0.89 CONTENDER
Organ Transplant Rejection #4 of 9 PHASE 2 Efgartigimod PH20 - prefilled syringe
SNY BIIB AZN
$5.2B 0.84 CONTENDER
Sjogren's Syndrome #4 of 10 PHASE 3 Efgartigimod PH20
NVS AMGN BMY
$0.3B 0.84 CONTENDER
Genodermatoses #4 of 4 PHASE 1 Efgartigimod
KRYS ABEO CSTL
—0 CONTENDER
Spinal Muscular Atrophy #5 of 7 PHASE 2 ARGX-119
BIIB NVS SRRK
$2.5B 0.91 CONTENDER
ALS #5 of 15 PHASE 2 ARGX-119
AMLX BIIB IONS
$1.2B 0.89 CONTENDER
Thyroid Disorders #5 of 11 PHASE 3 Efgartigimod PH20
VRDN AMGN ZLAB
$11.1B 0 CONTENDER
Systemic Sclerosis #6 of 21 PHASE 2 Efgartigimod PH20
AZN BMY MRK
$2.68B 0.82 FOLLOWER
Rare Neurological Disorders #9 of 46 PHASE 3 Efgartigimod PH20
IONS BIIB SRPT
$139.4B 0.83 CONTENDER
Leukemia #32 of 64 PHASE 2 Azacitidine + Cusatuzumab
AMGN LLY AZN
$4.28B 0 FOLLOWER
Rare Genetic Disorders #58 of 61 PHASE 1 Efgartigimod
BMRN ASND NVS
—0 FOLLOWER